Q3 2024 Neuland Laboratories Ltd Earnings Call Transcript
Key Points
- Neuland Laboratories Ltd (BOM:524558) reported a 46% increase in total income for Q3 FY24, reaching INR394.9 crores.
- EBITDA for the quarter stood at INR122.7 crores with a margin of 31.1%, reflecting a 10.8% increase over Q3 FY23.
- The company achieved a gross margin of 59.8% in Q3 FY24, up from 55.2% in Q3 FY23.
- Profit after tax for the quarter was INR80.7 crores, significantly higher than INR30.4 crores in Q3 FY23.
- Neuland Laboratories Ltd (BOM:524558) generated a free cash flow of INR129 crores for the nine months, using part of this to reduce debt by INR38.8 crores.
- The operating environment remains unpredictable, with potential fluctuations in revenues and EBITDA margins due to business mix and order inflow.
- The company experienced a slight lowering of vasopressin during the quarter due to receivables arising from Christmas and year-end holidays in developed markets.
- Neuland Laboratories Ltd (BOM:524558) anticipates modest growth in FY25 with some normalization of margins due to rising operating expenses and ongoing investments.
- The biotech funding crunch is still prevalent, potentially impacting early-stage pipeline projects.
- The company faces challenges in maintaining consistent growth and profitability due to factors like individual product performance, forex, raw material costs, geopolitical changes, and regulatory shifts.
Ladies and gentlemen, good day. Welcome to the Neuland Laboratories Limited Q3 and nine-month FY24 earnings conference call. (Operator Instructions) Note that this conference is being recorded.
I now hand the conference over to o Mr. Ravi Udeshi from Ernst & Young. Thank you, and over to you, sir.
Thank you, Muskan. Good evening, friends. We welcome you to the Q3 and nine months FY24 earnings conference call of Neuland Laboratories Limited. To take us through the results and to answer your questions, we have with us the top management from Neuland Laboratories represented by Mr. Sucheth Davuluri, Vice Chairman and CEO; Mr. Saharsh Davuluri, Vice Chairman and Managing Director; Mr. Abhijit Majumdar, CFO; and Mr. Sajeev Emmanuel Medikonda, Head, Corporate Planning and Strategy.
We will start the call with a brief overview of the financials by Mr. Abhijit Majumdar. And then, Saharsh will give you broad highlights of the business trends and what he is observing in the market. And post that, we will
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
